SCHEMBL190204

SCHEMBL190204

CCOC(=O)c1cnc(Nc2nc(C)cs2)cc1Oc1cccc2ccccc12

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GCK P35557 1/20 0.44
MAPT P10636 8/20 0.44
ALDH1A1 P00352 3/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
CCR4 P51679 1/20 0.43
CDC25B P30305 2/20 0.43
CDC25A P30304 1/20 0.43
CDC25C P30307 1/20 0.43
KDM4E B2RXH2 2/20 0.43
GAA P10253 1/20 0.43
KMT2A Q03164 3/20 0.42
MEN1 O00255 2/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
TP53 P04637 3/20 0.41
HPGD P15428 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL190826 0.89 CCR4 (0.46) GCKMAPTALDH1A1CCR4KDM4E
SCHEMBL190487 0.87 GCK (0.52) GCKKMT2AMEN1
SCHEMBL190724 0.83 CCR4 (0.51) GCKMAPTALDH1A1CCR4KDM4E
SCHEMBL192427 0.81 CCR4 (0.48) GCKMAPTALDH1A1CCR4KDM4E
SCHEMBL2660966 0.80 CCR4 (0.43) GCKMAPTALDH1A1SMN1; SMN2CCR4
SCHEMBL2660968 0.80 CCR4 (0.43) GCKMAPTALDH1A1SMN1; SMN2CCR4
SCHEMBL190793 0.79 CCR4 (0.43) GCKMAPTALDH1A1SMN1; SMN2CCR4
SCHEMBL190791 0.79 CCR4 (0.43) GCKMAPTALDH1A1SMN1; SMN2CCR4
SCHEMBL190792 0.79 CCR4 (0.43) GCKMAPTALDH1A1SMN1; SMN2CCR4
SCHEMBL12333204 0.79 MAPT (0.41) MAPTALDH1A1SMN1; SMN2CDC25BCDC25A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1986645-B1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC (US) 2012-01-04 EP disclosed
US-8022222-B2 Glucokinase activators ARRAY BIOPHARMA, INC. (US) 2011-09-20 US disclosed
US-8022222-B2 Glucokinase activators ARRAY BIOPHARMA, INC. (US) 2011-09-20 US disclosed
US-20090247526-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2009-10-01 US disclosed
US-20090247526-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2009-10-01 US disclosed
EP-1986645-A1 GLUCOKINASE ACTIVATORS Array Biopharma, Inc. (US) 2008-11-05 EP disclosed
WO-2007089512-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2007-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247526-A1 GLUCOKINASE ACTIVATORS GCKR, GCK, GALK1 GCK 2/4885MAPT 4375/4885ALDH1A1 1869/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.